市場調査レポート

商品コード

1447730

多形性膠芽細胞腫治療市場の評価：薬剤・治療法・エンドユーザー・地域別の機会および予測 (2017～2031年)

Glioblastoma Multiforme Treatment Market Assessment, By Drug, By Treatment, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月11日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 228 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,420円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,532円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,285,432円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の多形性膠芽細胞腫治療の市場規模は、2023年の29億1,000万米ドルから、2024年から2031年の予測期間中は8.78%のCAGRで推移し、2031年には57億1,000万米ドルの規模に成長すると予測されています。同市場は近年著しい成長を遂げており、今後も力強い成長ペースを維持すると予測されています。

世界の多形性膠芽細胞腫治療市場の成長は、人口における多形性膠芽細胞腫の有病率の増加、革新的な治療薬の開発、製薬・創薬産業の著しい成長など、いくつかの要因によって牽引されています。政府のイニシアティブ、高品質で効率的な薬剤を開発するための主要参入事業者による投資の増加、支援的な規制の枠組み、医療機器メーカーと製薬会社の共同事業なども世界の多形性膠芽細胞腫治療市場の成長をさらに促進する見通しです。

多形性膠芽細胞腫の有病率の増加

世界の多形性膠芽細胞腫の症例数の増加により、多形性膠芽細胞腫治療の需要は著しく増加しています。膠芽細胞腫は転移が速く、さらなる合併症を引き起こす癌の一種であるため、世界的に癌患者の死因の上位を占めています。UT Southwestern Medical Centerに掲載された論文によると、世界では毎年30万例以上の膠芽細胞腫が診断されています。成人の原発性悪性脳腫瘍の中でもっとも一般的であるとしています。膠芽細胞腫患者の生存期間は平均15～18ヶ月であり、患者の生存率を向上させる効率的な治療プロセスをもたらすR&Dの必要性がさらに強調されています。

医薬品開発プロセスの迅速化のためのAIの統合

製薬企業におけるAIの活用は、医薬品開発プロセスにおける合成経路の解析や生成、臨床試験デザインの最適化など、その大きな可能性により、重要性を増しています。多形性膠芽細胞腫治療市場の新興国市場の大手企業は、AIや機械学習などの最新の先端技術を利用してR&Dプロセスを強化し、癌の治療プロセスにおいて有益な、より効率的な治療薬をもたらすことに継続的に取り組んでいます。

治療法では放射線療法が市場を独占

多形性膠芽細胞腫患者に対するさまざまな治療法の中では、放射線療法の適用が大幅に増加しています。放射線療法は、多形性膠芽細胞腫の治療において重要な役割を果たしています。腫瘍を外科的に除去した後、残存する癌細胞を死滅させ、将来的な癌細胞の増殖を抑えるために、放射線療法単独または化学療法との併用が推奨されています。放射線療法をより効率的に行うための革新的な治療薬の開発には、いくつかの企業が携わっています。例えば、2023年12月、Shuttle Pharmaceuticals Holdings, Inc.は、臨床試験の次の段階におけるロピドクスウリジンの開発を支援するため、FDAに治験薬（IND）を申請したと発表しました。ロピドクスウリジンは放射線増感剤であり、多形性膠芽細胞腫の放射線療法に使用されます。この革新的なアプローチは、癌の生存率を高め、患者の寿命を延ばすことを目的としています。

当レポートでは、世界の多形性膠芽細胞腫治療の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
薬剤別
- テモゾロミド
- ロムスチン
- ベバシズマブ
- その他
治療法別
- 手術
- 放射線療法
- 化学療法
- 標的療法
- その他
エンドユーザー別
- 病院
- 外来手術センター
- その他
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
企業別の市場シェア

第5章世界の多形性膠芽細胞腫治療市場の展望：地域別

北米
欧州
南米
アジア太平洋
中東・アフリカ

第6章市場マッピング

薬剤別
治療法別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長阻害要因 (課題・抑制要因)

第9章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析（主要企業）
特許分析（該当する場合）

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

F. Hoffmann-La Roche Ltd
Amgen Inc.
Merck & Co., Inc.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
Azurity Pharmaceuticals, Inc.
Bristol-Myers Squibb Co
Eli Lilly and Company
Lantern Pharma Inc.
Karyopharm Therapeutics Inc.

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 2.Global Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 3.Global Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 4.Global Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 5.Global Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 6.Global Glioblastoma Multiforme Treatment Market Share (%), By Region, 2017-2031F
Figure 7.North America Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 8.North America Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 9.North America Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 10.North America Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 11.North America Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 12.North America Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 13.United States Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 14.United States Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 15.United States Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 16.United States Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 17.United States Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 18.Canada Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 19.Canada Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 20.Canada Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 21.Canada Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 22.Canada Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 23.Mexico Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 24.Mexico Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 25.Mexico Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 26.Mexico Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 27.Mexico Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 28.Europe Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 29.Europe Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 30.Europe Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 31.Europe Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 32.Europe Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 33.Europe Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 34.Germany Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 35.Germany Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 36.Germany Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 37.Germany Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 38.Germany Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 39.France Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 40.France Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 41.France Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 42.France Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 43.France Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 44.Italy Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 45.Italy Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 46.Italy Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 47.Italy Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 48.Italy Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 49.United Kingdom Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 50.United Kingdom Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 51.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 52.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 53.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 54.Russia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 55.Russia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 56.Russia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 57.Russia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 58.Russia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 59.Netherlands Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 60.Netherlands Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 61.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 62.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 63.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 64.Spain Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 65.Spain Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 66.Spain Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 67.Spain Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 68.Spain Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 69.Turkey Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 70.Turkey Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 71.Turkey Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 72.Turkey Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 73.Turkey Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 74.Poland Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 75.Poland Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 76.Poland Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 77.Poland Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 78.Poland Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 79.South America Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 80.South America Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 81.South America Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 82.South America Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 83.South America Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 84.South America Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 85.Brazil Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 86.Brazil Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 87.Brazil Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 88.Brazil Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 89.Brazil Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 90.Argentina Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 91.Argentina Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 92.Argentina Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 93.Argentina Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 94.Argentina Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 95.Asia-Pacific Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 96.Asia-Pacific Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 97.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 98.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 99.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 100.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 101.India Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 102.India Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 103.India Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 104.India Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 105.India Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 106.China Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 107.China Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 108.China Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 109.China Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 110.China Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 111.Japan Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 112.Japan Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 113.Japan Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 114.Japan Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 115.Japan Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 116.Australia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 117.Australia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 118.Australia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 119.Australia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 120.Australia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 121.Vietnam Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 122.Vietnam Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 123.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 124.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 125.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 126.South Korea Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 127.South Korea Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 128.South Korea Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 129.South Korea Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 130.South Korea Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 131.Indonesia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 132.Indonesia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 133.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 134.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 135.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 136.Philippines Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 137.Philippines Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 138.Philippines Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 139.Philippines Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 140.Philippines Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 141.Middle East & Africa Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 142.Middle East & Africa Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 143.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 144.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 145.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 146.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 147.Saudi Arabia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 148.Saudi Arabia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 149.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 150.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 151.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 152.UAE Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 153.UAE Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 154.UAE Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 155.UAE Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 156.UAE Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 157.South Africa Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 158.South Africa Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 159.South Africa Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 160.South Africa Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 161.South Africa Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 162.By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163.By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11137

Global glioblastoma multiforme treatment market is projected to witness a CAGR of 8.78% during the forecast period 2024-2031, growing from USD 2.91 billion in 2023 to USD 5.71 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Growth in global glioblastoma multiforme treatment market is being driven by several factors such as increase in the prevalence of glioblastoma multiforme among the population, the development of innovative therapeutical drugs, and tremendous growth in the pharmaceutical and drug discovery industry. Government initiatives, growing investments by key market players to develop quality and efficient drugs, along with a supportive regulatory framework and collaborative ventures between medical device manufacturers and pharmaceutical companies will further promote the growth of the global glioblastoma multiforme treatment market.

The global glioblastoma multiforme treatment market is significantly undergoing robust growth due to the increasing prevalence of glioblastoma multiforme worldwide. As glioblastoma multiforme is a fast-growing tumor, it is highly essential to get treatment as early as possible to develop any fatal condition. Glioblastoma multiforme treatment methods such as surgery, chemotherapy, and radiation therapy play a crucial role in increasing the life expectancy of the patients. With the growing cases of glioblastoma, there is an increased demand for glioblastoma multiforme treatments due to which many leading players are continuously involved in launching innovative and efficient therapeutical drugs in their cancer treatment product portfolio, which is further propelling the growth of the global glioblastoma multiforme treatment market.

Government initiatives such as granting funds are being initiated to improve research and development in the market to improve medical facilities and provide efficient treatment to the patients. Product launches by key market players, along with increased collaboration activities such as mergers and acquisitions, partnership agreements, and new distribution agreements, drive the global glioblastoma multiforme treatment market. Moreover, several market leaders are undergoing extensive research and development in the market to launch innovative and efficient drugs. Celldex Therapeutics that develops targeted immunotherapy and biologics for the treatment of different types of cancers, announced that its latest drug "Varlilumab" is under clinical trial phase II and is most likely to progress into phase III.

Increasing Prevalence of Glioblastoma Multiforme

The demand for glioblastoma multiforme treatment is increasing significantly due to the rising number of glioblastoma multiforme cases worldwide. Glioblastoma is a leading cause of death among the cancer patients globally, as it is a type of cancer that spreads faster, leading to further health complications. According to an article published in "UT Southwestern Medical Center", globally, more than 300,000 cases of glioblastoma are diagnosed every year. It states that it is the most common primary malignant brain cancer in the adult population. The survival time for glioblastoma patients is only 15 to 18 months on an average, which further emphasizes the need for research and development to bring efficient treatment process that can increase the survival rate of the patients.

Integration of AI For Expediting Drug Development Process

The use of artificial intelligence in pharmaceutical companies is becoming more significant, due to its huge potential to analyze and generate synthesis pathways during the drug development process, as well as optimize clinical trial designs. Leading players in the glioblastoma multiforme treatment market are continuously involved in using the latest advanced technologies such as artificial intelligence and machine learning to enhance the research and development process, to bring more efficient therapeutic drugs, that can be beneficial in the treatment process of cancer.

For instance, in October 2023, Lantern Pharma Inc., using its AI-based platform, "RADR", announced that its latest innovative drug "LP-184" for the treatment of glioblastoma was published in the American Association for Cancer Research Journal. It states that LP-184 is a unique small molecule that has highly efficient CNS penetration and low nanomolar activity. With the help of its AI platform RADR, LP-184 is developed in such a way that it can repair damaged DNA. Moreover, it has been proven to be effective for patients with temozolomide resistance.

Radiation Therapy Dominates the Market in Terms of Treatment Methods

Among the different treatment methods for glioblastoma multiforme patients, the application of radiation therapy is increasing significantly. Radiation therapy plays a crucial part in the treatment of glioblastoma multiforme. After the surgical removal of a tumor, radiation therapy alone or in combination with chemotherapy is recommended to kill the remaining cancer cells and limit the growth of cancer cells in the future. Several companies are involved in developing innovative therapeutics to make radiation therapies more efficient. For instance, in December 2023 Shuttle Pharmaceuticals Holdings, Inc. announced application submission of an investigational new drug (IND) to the FDA, to support the company in the development of Ropidoxuridine in the next phase of the clinical trial. Ropidoxuridine is a radiation sensitizer, that is used in radiation therapy to treat glioblastoma multiforme. The innovative approach aims to increase cancer survival rates and prolong a patient's life.

Hospitals Hold a Major Share in Glioblastoma Multiforme Treatment Market

Among the end-user segment, hospitals account for the highest market share in the global glioblastoma multiforme treatment market. The increasing global population and rising number of hospitals are expected to cater to the demands and the dominance of the segment in the market. Glioblastoma multiform is an aggressive brain tumor that requires different treatments such as surgery, chemotherapy, and radiation therapy. Hospitals provide all these facilities, along with highly qualified surgeons and healthcare providers, which helps smoothen a patient's journey throughout the entire pathway from diagnosis to follow up and assessment. As the prevalence of cancer such as glioblastoma multiforme is increasing, the demand for hospitals in developed as well as developing countries are increasing, due to which countries are increasing the number of hospitals with advanced diagnostics and treatment facilities. For instance, according to the American Hospital Association, in the year 2023, there were 6,129 hospitals in the United States and more hospitals are under construction. Increased availability of a variety of treatment facilities in the healthcare setting, along with increased trust among the population regarding the reliability and quality of healthcare facilities provided in the hospitals is further driving the growth of hospital segment in the overall market.

North America Holds Significant Market Share

North America dominates global glioblastoma multiforme treatment market, due to its well-developed and highly efficient healthcare infrastructure and availability of the latest and advanced surgical techniques and therapeutical drugs for the treatment of glioblastoma multiforme. The growing prevalence of glioblastoma multiforme among the United States population is the prime factor, that is driving the growth of this market.

For instance, according to the "National Brain Tumor Society", in the United States, more than 10,000 individuals are affected by glioblastoma multiforme every year and it is estimated that out of all primary malignant brain tumors, 50.1% account for glioblastoma multiforme. The increasing prevalence requires efficient treatment such as surgeries, chemotherapy, and radiation therapy to increase the life span of the patients affected by this disease. Due to this, the demand for glioblastoma multiforme treatment is increasing in North America. Additionally, increased research and development in the market, along with the presence of key market players such as Amgen Inc and Merck & Co. further accelerate the demand for the global glioblastoma multiforme treatment market in the region.

Future Market Scenario (2024 - 2031F)

The global glioblastoma multiforme treatment market is expected to grow in the future, primarily due to increasing prevalence of glioblastoma multiforme worldwide. As the prevalence is increasing, pharmaceutical companies are constantly involved in extensive research and development of innovative therapeutical drugs for the treatment of the disease, along with mergers and acquisitions activities to enhance their product portfolio and expand their global market.

Additionally, the growth of the pharmaceutical industry, increased investments by organizations and government, frequent product launches, and increased FDA approvals by the regulatory bodies further lead to the growth of the global glioblastoma multiforme treatment market. For instance, in January 2024, Roche announced that its latest drug "Atezolizumab" is under clinical trial phase II and is most likely to get the FDA approval soon. The drug is expected to provide efficient treatment to the patients suffering from glioblastoma multiforme. These frequent product launches and favorable regulatory frameworks are further expected to escalate the growth of the market in the forecast period.

Key Players Landscape and Outlook

In the glioblastoma multiforme treatment market, pharmaceutical firms and biotechnological companies are consistently forming strategic partnerships and distribution agreements to enhance their productivity and global business. These collaboration activities play a crucial role in propelling the global glioblastoma multiforme treatment market's expansion. The strategic partnerships agreements, enable firms to gain in-depth insights into the market, strategically use each other's resources, markets, and technologies, and invest in research and development activities to bring innovative drug discovers and technological advancements in the treatment methods. Distribution agreements allow companies to expand their market presence globally. These collaborative initiatives promote innovation and expertise in product development, which improves patient health outcomes and contributes to the enduring and robust growth of the global glioblastoma multiforme treatment market.

For instance, in September 2023, Double Bond Pharmaceutical International AB, which is a pharmaceutical company that develops therapeutical drugs against cancer, announced its collaboration with Vivo Biopharma LLC, which is a subsidiary of Sauvie Inc. The collaboration will allow asset purchase and transition agreements for DBP's SI-053, which is a locally acting formulation of temozolomide, developed for the treatment of glioblastoma. As this latest drug has the potential to increase survival rate in patients suffering from glioblastoma, it is expected that the agreement will provide quality and advanced treatment to cancer patients and will support in elevating the market globally.

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Glioblastoma Multiforme Treatment Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1.By Value
- 4.1.2.By Volume
4.2.By Drug
- 4.2.1.Temozolomide
- 4.2.2.Lomustine
- 4.2.3.Bevacizumab
- 4.2.4.Others
4.3.By Treatment
- 4.3.1.Surgery
- 4.3.2.Radiation
- 4.3.3.Chemotherapy
- 4.3.4.Targeted Therapy
- 4.3.5.Others
4.4.By End-user
- 4.4.1.Hospital
- 4.4.2.Ambulatory Surgical Centers
- 4.4.3.Others
4.5.By Region
- 4.5.1.North America
- 4.5.2.Europe
- 4.5.3.Asia-Pacific
- 4.5.4.South America
- 4.5.5.Middle East and Africa
4.6.By Company Market Share (%), 2023

5.Global Glioblastoma Multiforme Treatment Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Drug
  - 5.1.2.1.Temozolomide
  - 5.1.2.2.Lomustine
  - 5.1.2.3.Bevacizumab
  - 5.1.2.4.Others
- 5.1.3.By Treatment
  - 5.1.3.1.Surgery
  - 5.1.3.2.Radiation
  - 5.1.3.3.Chemotherapy
  - 5.1.3.4.Targeted Therapy
  - 5.1.3.5.Others
- 5.1.4.By End-user
  - 5.1.4.1.Hospital
  - 5.1.4.2.Ambulatory Surgical Centers
  - 5.1.4.3.Others
- 5.1.5.United States*
  - 5.1.5.1.Market Size & Forecast
  - 5.1.5.1.1.By Value
  - 5.1.5.1.2.By Volume
  - 5.1.5.2.By Drug
  - 5.1.5.2.1.Temozolomide
  - 5.1.5.2.2.Lomustine
  - 5.1.5.2.3.Bevacizumab
  - 5.1.5.2.4.Others
  - 5.1.5.3.By Treatment
  - 5.1.5.3.1.Surgery
  - 5.1.5.3.2.Radiation
  - 5.1.5.3.3.Chemotherapy
  - 5.1.5.3.4.Targeted Therapy
  - 5.1.5.3.5.Others
  - 5.1.5.4.By End-user
  - 5.1.5.4.1.Hospital
  - 5.1.5.4.2.Ambulatory Surgical Centers
  - 5.1.5.4.3.Others
- 5.1.6.Canada
- 5.1.7.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1.Germany
- 5.2.2.France
- 5.2.3.Italy
- 5.2.4.United Kingdom
- 5.2.5.Russia
- 5.2.6.Netherlands
- 5.2.7.Spain
- 5.2.8.Turkey
- 5.2.9.Poland
5.3.Asia-Pacific
- 5.3.1.India
- 5.3.2.China
- 5.3.3.Japan
- 5.3.4.Australia
- 5.3.5.Vietnam
- 5.3.6.South Korea
- 5.3.7.Indonesia
- 5.3.8.Philippines
5.4.South America
- 5.4.1.Brazil
- 5.4.2.Argentina
5.5.Middle East & Africa
- 5.5.1.Saudi Arabia
- 5.5.2.UAE
- 5.5.3.South Africa

6.Market Mapping, 2023

6.1.By Drug
6.2.By Treatment
6.3.By End-user
6.4.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.5.1.Supplier Power
- 7.5.2.Buyer Power
- 7.5.3.Substitution Threat
- 7.5.4.Threat from New Entrant
- 7.5.5.Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Clinical Trials
9.2.Patent Landscape
9.3.Regulatory Approvals
9.4.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)
10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.F. Hoffmann-La Roche Ltd
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.Amgen Inc.
13.3.Merck & Co., Inc.
13.4.Pfizer Inc.
13.5.Sun Pharmaceutical Industries Limited
13.6.Azurity Pharmaceuticals, Inc.
13.7.Bristol-Myers Squibb Co
13.8.Eli Lilly and Company
13.9.Lantern Pharma Inc.
13.10.Karyopharm Therapeutics Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

多形性膠芽細胞腫治療市場の評価：薬剤・治療法・エンドユーザー・地域別の機会および予測 (2017～2031年)

Glioblastoma Multiforme Treatment Market Assessment, By Drug, By Treatment, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の多形性膠芽細胞腫治療市場の展望

第5章世界の多形性膠芽細胞腫治療市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Glioblastoma Multiforme Treatment Market Outlook, 2017-2031F

5.Global Glioblastoma Multiforme Treatment Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

多形性膠芽細胞腫治療市場の評価：薬剤・治療法・エンドユーザー・地域別の機会および予測 (2017～2031年)

Glioblastoma Multiforme Treatment Market Assessment, By Drug, By Treatment, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の多形性膠芽細胞腫治療市場の展望

第5章 世界の多形性膠芽細胞腫治療市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Glioblastoma Multiforme Treatment Market Outlook, 2017-2031F

5.Global Glioblastoma Multiforme Treatment Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の多形性膠芽細胞腫治療市場の展望

第5章世界の多形性膠芽細胞腫治療市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項